Population pharmacokinetics and pharmacodynamics of meropenem in patients with severe pulmonary infection

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900020672

Enrollment

Unknown

Registered

2019-01-12

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary infection

Interventions

Case series:meropenem

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Patients with severe pulmonary infection; (2) Indications for meropenem clearly; (3) Isolated Gram negative bacillus by specimen culture. (4) Meropenem continuous duration more than 2 days; (5) At least one steady-state meropenem serum concentration ; (6) Aged at least 18 years.

Exclusion criteria

Exclusion criteria: (1) pregnant or lactating women; (2) Allergy to carbapenems; (3) Simultaneous use of sodium valproate; (4) Infected by gram positive cocci, virus, fungal before joining the group.

Design outcomes

Primary

Measure	Time frame
Blood concentration;	—

Countries

China

Contacts

Public ContactLuo Hong

The Second Xiangya Hospital of Central South University

luohong1003@163.com+86 13607435199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026